Enanta Pharmaceuticals | ENTA - Creditori Commerciali

Prezzo Delle Azioni
12.69
Cambio Giornaliero
0.18 1.44%
Mensile
-13.97%
Annuale
104.68%
Q1 Previsione
12.13




Creditori Commerciali Cambiamento Data
AbbVie USD 3.59B 28.65B 2025-12
Amgen USD 20.89B 1.25B 2025-12
Anika Therapeutics USD 6.04M 1.31M 2025-12
Arrowhead Research USD 32.94M 15.26M 2025-12
AstraZeneca USD 25.28B 252M 2025-12
BioCryst Pharmaceuticals USD 15.83M 10.26M 2025-12
Biogen USD 432M 18.9M 2025-12
Bristol-Myers Squibb USD 4.29B 1.14B 2025-09
Enanta Pharmaceuticals USD 1.88M 63K 2025-12
Gilead Sciences USD 808M 226M 2025-09
GlaxoSmithKline GBP 15.38B 294M 2025-12
Halozyme Therapeutics USD 20.9M 5.54M 2025-12
Heron Therapeutics USD 8.99M 3.02M 2025-12
Immunic USD 7.92M 25K 2025-09
Incyte USD 1.63B 1.46B 2025-12
Insmed USD 79.91M 316K 2025-12
Ionis Pharmaceuticals USD 14.33M 8.47M 2025-09
J&J USD 11.99B 2.37B 2025-12
Karyopharm Therapeutics USD 5.39M 2.8M 2025-09
Ligand Pharmaceuticals USD 3.24M 24.52M 2025-12
Merck USD 4.15B 102M 2025-09
Neurocrine Biosciences USD 545.5M 425.6M 2025-12
Novartis USD 4.46B 99M 2025-12
Novavax USD 24.58M 9.35M 2025-12
Pfizer USD 5.02B 142M 2025-09
PTC Therapeutics USD 45.49M 8.87M 2025-12
Roche Holding CHF 5.78B 1.27B 2025-12
Sarepta Therapeutics USD 280.84M 186.83M 2025-12
Vertex Pharmaceuticals USD 3.43B 600.9M 2025-12